A randomized trial comparing the safety and efficacy of adriamycin and cyclophosphamide followed by Taxol (AC-T) to that of adriamycin and cyclophosphamide followed by Taxol plus Herceptin (AC-T+H) in node-positive breast cancer patients who have tumors that overexpress HER2.
Latest Information Update: 03 Sep 2024
At a glance
- Drugs Trastuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Jun 2023 Results of pooled analysis from NCT00045032, ISRCTN76560285, NCT00005970, NCT00004067, NCT00054587, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 28 Apr 2021 Status changed from active, no longer recruiting to completed.
- 28 Aug 2020 Results (n=1770) of pooled analysis assessing long-term outcomes (iDFS and OS) of patients from APT trial (NCT00542451) vs matched external controls from five studies ((BCIRG 006 [NCT00021255], NSABP-B31 [NCT00004067], HERA [NCT00045032], N-9831 [NCT00005970], and APHINITY [NCT01358877])), published in the Annals of Oncology.